🇺🇸 FDA
Pipeline program

Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)

VGFTe-RVO-1027

Phase 3 small_molecule completed

Quick answer

Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) for Branch Retinal Vein Occlusion is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Branch Retinal Vein Occlusion
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials